| In the majority of cases, DK/DKA occurred within 180 days after initiation of SGLT2i therapy in female and/or long-standing T2DM patients with known precipitating factors. |
| The absolute number of SGLT2i-associated DK/DKA cases are expected to rise with the increasing use of SGLT2i. |
| The incidence of this serious but potentially preventable ADR could be reduced through appropriate clinical vigilance and patient education. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.